Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749138 · ClinicalTrials.gov registry record · Phase 1
Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy
A Phase 1 study, sponsored by Bader, Ted, M.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00749138 is a Phase 1 study that has completed, run by Bader, Ted, M.D.. The registered enrollment target is 18 participants.
The verdict
NCT00749138, a Phase 1 study, has completed, sponsored by Bader, Ted, M.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.
Interventions
- DRUG tamoxifen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749138
The ClinicalTrials.gov registry entry for NCT00749138 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bader, Ted, M.D., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tamoxifen is the first listed.
NCT00749138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00749138 about?
NCT00749138 is a clinical study titled "Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy". A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.
What is the current status of trial NCT00749138?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2008-11. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00749138?
The interventions under investigation include: tamoxifen (DRUG).
Who is sponsoring clinical trial NCT00749138?
This trial is sponsored by Bader, Ted, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.